India’s Cadila Healthcare, which has been suffering on the earnings front, is amalgamating four subsidiaries under its roof to reduce overheads from managing separate entities and avoid duplication of efforts after posting weak second-quarter earnings.

Sun Pharmaceutical Industries is back before US courts as it contests US antitrust charges filed by plaintiffs over the delayed market entry of generic versions of three major drugs.

GemVax unveils positive topline results for South Korean Phase II study of novel peptide drug targeting patients with moderate to severe Alzheimer’s disease, raising hopes for the upcoming US trials.